Samsung Biologics shares buoyed by Biogen's successful Alzheimer treatment test
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Shares of Samsung Biologics started Friday’s trading session a bit higher after a 6 percent jump in the previous day, taking back the 800,000 won ($559) range in six days. It inched up 0.62 percent at 818,000 won.
On Thursday (local time), Biogen and Eisai announced that the anti-amyloid antibody lecanemab met its primary endpoint by reducing clinical decline relative to a placebo by 27 percent. Biogen shares jumped nearly 40 percent on the announcement.
Biogen plans to submit for full approval of lecanemab to the U.S. FDA by the first quarter of next year.
Analysts say the clinical progress of Biogen will benefit global contract manufacturers like Samsung Biogen. NH Investment & Securities estimates that more than 95 percent of Samsung Biologics’ drug substance sales come from contract manufacturing of monoclonal antibody therapies like lecanemab.
The overall monoclonal antibody therapy market is projected to grow by 9 to 10 percent annually and this has a significant impact on the permanent growth rate of contract manufacturers as a stock price is valuated on the expected future cash flows discounted in today’s value on a per-share basis, said NH analyst Park Byung-kuk.
Samsung Biologics has a long-standing partnership with Biogen. They established Samsung Bioepis in a joint venture, which was fully acquired by Samsung Biologics in January.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Korea’s M&A deals contract 67% in Q3 amid higher borrowing costs - Pulse by Maeil Business News Korea
- South Korea considers electricity bill hikes - Pulse by Maeil Business News Korea
- KG Group Chair Kwak, new SsangYong CEO, meets SNAM CEO for KD supply - Pulse by Maeil Business News Korea
- Kospi touches this year’s new low below 2,150 on Friday - Pulse by Maeil Business News Korea
- S. Korea’s factory output fall for 2nd mo in Aug., consumption, capex jump - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 아시아 최초 ‘다인종·다문화 국가’ 한국 [편집장 레터]
- NCT 태일, 불미스러운 일로 팀 탈퇴…SM “엄중함 인지”[공식입장][전문] - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이